VAG
CPRX

VisionPoint Advisory Group’s Catalyst Pharmaceutical CPRX Stock Holding History

VisionPoint Advisory Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,176
Closed -$68.3K – 226
2024
Q4 		$68.3K Hold
3,176
– – 0.02% 263
2024
Q3 		$63.1K Hold
3,176
– – 0.02% 230
2024
Q2 		$49.2K Hold
3,176
– – 0.02% 269
2024
Q1 		$50.6K Hold
3,176
– – 0.02% 265
2023
Q4 		$53.4K Hold
3,176
– – 0.02% 235
2023
Q3 		$37.1K Hold
3,176
– – 0.02% 272
2023
Q2 		$42.7K Buy
+3,176
New +$45.7K 0.02% 225

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

VisionPoint Advisory Group's CPRX Position: Q1 2025 in Review

VisionPoint Advisory Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 3,176 shares — an estimated $68.3K sold.

VisionPoint Advisory Group first reported a position in CPRX in Q2 2023 and held it in 7 quarters. The position peaked at $68.3K in Q4 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • VisionPoint Advisory Group reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • VisionPoint Advisory Group sold 3,176 Catalyst Pharmaceutical shares in Q1 2025, an estimated $68.3K.
  • VisionPoint Advisory Group first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 7 quarters.
  • VisionPoint Advisory Group's Catalyst Pharmaceutical position peaked at $68.3K in Q4 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on VisionPoint Advisory Group's 13F filing for Q1 2025, filed 23 Apr 2025.